Inhibitor control

Manufactured by Qiagen

Sourced in Germany

The Inhibitor Control is a laboratory equipment product designed to detect and monitor inhibitors in various sample types. It serves as a quality control tool to ensure the reliability and accuracy of analytical results.

Automatically generated - may contain errors

Lab products found in correlation

Sorafenib, by Santa Cruz Biotechnology (1 mentions) Tcf reporter plasmid kit, by Merck Group (1 mentions) Doxorubicin, by Santa Cruz Biotechnology (1 mentions) Mir 23a inhibitor, by Qiagen (1 mentions) Mircury lna inhibitor, by Qiagen (1 mentions) Hiperfect, by Thermo Fisher Scientific (1 mentions) Opti mem medium, by Thermo Fisher Scientific (1 mentions) Hiperfect, by Qiagen (1 mentions)

Close spelling variants of this product

MiRCURY LNA miRNA Inhibitor Control (5 citations) MiRCURY LNA Power Inhibitor Control (4 citations) MiRCURY LNA microRNA inhibitor control (3 citations) MiRCURY LNA inhibitor Control (3 citations) Control miRNA inhibitor (2 citations) MiRCURY LNA miRNA Power Inhibitor Control (2 citations) MiRNA inhibitor control (339126) (2 citations) MiRCURY LNA miRNA inhibitor control NegativeControl A (2 citations)

4 protocols using inhibitor control

Inhibition of miR-27b-3p in C2C12 and PACs

Check if the same lab product or an alternative is used in the 5 most similar protocols

For transfection of anti‐miR‐27b‐3p oligonucleotides in C2C12 cells, cells were seeded and cultured to a density of 60–70%. Medium was changed and cells were transfected with miRCURY LNA Inhibitor or Inhibitor Control (Qiagen, Germany) for 72 h with a final concentration of 30 nM. Cells were transfected before initiation of differentiation. RNA was harvested on d0, d4 and d7.
Visceral PACs were seeded in 6‐well plates. At a density of 80%, medium was changed, and cells were transfected with miRCURY LNA Inhibitor containing appropriate siRNA or Inhibitor Control (Qiagen, Germany) for 72 h with a final concentration of 30 nM. Then, cells were differentiated for 14 days as described. Cells were harvested and media collected on d0, d3, d7, d10 and d14.
Expression levels of miR‐27b‐3p, miR‐375, miR‐424‐5p and related genes caused by miRNA depletion were analysed by RT‐qPCR (all primers are listed in Table S2).

Krauss T., Heisz S., Honecker J., Prokopchuk O., Martignoni M., Janssen K., Claussnitzer M., Hauner H, & Seeliger C. (2023). Specific miRNAs are associated with human cancer cachexia in an organ‐specific manner. Journal of Cachexia, Sarcopenia and Muscle, 14(3), 1381-1394.

+ Open protocol

+ Expand

Plasmid-Based Gene Regulation Experiments

Check if the same lab product or an alternative is used in the 5 most similar protocols

The HA/SOX7, GFP/SOX7, DSM/CTNNB1 and DSM/TCF4 expressing plasmid were purchased from Invitrogen (USA). The Myc/CTNNB1, Myc/TCF4, Wnt1 expressing plasmid were purchased from Origene (USA). The TCF Reporter Plasmid Kit were brought from Millipore (USA). MiR-452 mimic, miR-452 inhibitor, mimic control and inhibitor control were from Qiagen (Germany). Doxorubicin and Sorafenib were purchased from Santa Cruz (USA). ATRA was obtained from Sigma (USA). Lipofectamine2000 was used for cell transfection according to the manufacturer's instructions.

Zheng Z., Liu J., Yang Z., Wu L., Xie H., Jiang C., Lin B., Chen T., Xing C., Liu Z., Song P., Yin S., Zheng S, & Zhou L. (2016). MicroRNA-452 promotes stem-like cells of hepatocellular carcinoma by inhibiting Sox7 involving Wnt/β-catenin signaling pathway. Oncotarget, 7(19), 28000-28012.

+ Open protocol

+ Expand

Hypoxia-Induced miR-23a Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

The PASMCs were cultured for 24 h with DMEM containing 0.5% FBS before transfection. Cells transfected with miR-23a inhibitor (100 nM) (Qiagen, Inc.) were designated as the miR-23a inhibitor group.
Cells that transfected with inhibitor control (100 nM) (Qiagen, Inc.) were designated as the inhibitor control (ctrl) group, and cells with transfection reagent (equal volume) were designated as the vehicle group. All the groups were placed in an anoxia incubator containing 3% O₂ and were incubated for 48 h. Cells transfected with miR-23a mimic (100 nM) were designated as the miR-23a mimic group, and cells transfected with mimic control (100 nM) were designated as the mimic ctrl group. Cells with transfection reagent (equal volume) were designated as the blank control group, or vehicle. All groups were incubated in a normoxia incubator containing 21% O₂ for 48 h.

Yan L., Gao H., Li C., Han X, & Qi X. (2016). Effect of miR-23a on anoxia-induced phenotypic transformation of smooth muscle cells of rat pulmonary arteries and regulatory mechanism. Oncology Letters, 13(1), 89-98.

+ Open protocol

+ Expand

miRNA-29c-3p Modulation in Lung Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

LC cells were plated 24 h before transfection in Ham’s F10 medium and transfected at a density of ~50–60% confluency (HiPerFect; Qiagen, Germantown, MD, USA) following the manufacturer’s instructions. In brief, 10 nM of miRNA-29c-3p mimic or miRNA-29c-3p inhibitor with 2.5uL HiPerFect were diluted in 1mL serum-free OPTIMEM medium(Invitrogen), then incubated for 15 min at room temperature and transferred to the appropriate well with LC cells. The cells were then incubated overnight at 37 °C in 5% CO_2–95% air. The efficiency of the transfection was confirmed by qPCR. Negative controls consisted of cells with no treatment, non-targeting control for mimic experiments, and inhibitor control (Qiagen, Germantown, MD, USA) for inhibitor experiments. The miRNA-29c-3p mimic are double-stranded RNA oligonucleotides designed to mimic endogenously mature miRNA-29c activity. The miR-29c-3p inhibitors are single-strand RNA oligonucleotides designed to inhibit miRNA activity.

Lopez N.N., Rangan R., Clark A.F, & Tovar-Vidales T. (2021). Mirna Expression in Glaucomatous and TGFβ2 Treated Lamina Cribrosa Cells. International Journal of Molecular Sciences, 22(12), 6178.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!